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is aOBJECTIVES The aim of this study was to assess the safety and effectiveness of directional atherectomy (DA) for
endovascular treatment of peripheral arterial disease (PAD) in infrainguinal arteries in patients with claudication or critical
limb ischemia.
BACKGROUND To date, no prospective, multicenter, independently-adjudicated study has evaluated the effectiveness
and durability of DA in the treatment of PAD. Previous DA studies have not been prospectively powered to evaluate any
differences in outcomes in patients with and without diabetes.
METHODS DEFINITIVE LE (Determination of EFfectiveness of the SilverHawk PerIpheral Plaque ExcisioN System (SIlver-
HawkDevice) for theTreatmentof InfrainguinalVEssels /LowerExtremities)prospectivelyenrolledsubjectsat47multinational
centers with an infrainguinal lesion length up to 20 cm. Primary endpoints were deﬁned as primary patency at 12 months for
claudicants and freedom from major unplanned amputation for critical limb ischemia (CLI) subjects. A pre-speciﬁed statistical
hypothesis evaluated noninferiority of primary patency in diabetic versus nondiabetic claudicants. Independent angiographic
and sonographic core laboratories assessed outcomes, and events were adjudicated by a clinical events committee.
RESULTS A total of 800 subjects were enrolled. The 12-month primary patency was 78% (95% conﬁdence interval:
74.0% to 80.6%) in claudicants, with a 77% rate in the diabetic subgroup versus 78% in the nondiabetic subgroup
(noninferior, p < 0.001). The rate of freedom from major unplanned amputation of the target limb at 12 months in CLI
subjects was 95% (95% conﬁdence interval: 90.7% to 97.4%). Periprocedural adverse events included embolization
(3.8%), perforation (5.3%), and abrupt closure (2.0%). The bail-out stent rate was 3.2%.
CONCLUSIONS The DEFINITIVE LE study demonstrated that DA is a safe and effective treatment modality at 12 months
for a diverse patient population with either claudication or CLI. Furthermore, DA was shown to be noninferior for treating
PAD in patients with diabetes compared with those without diabetes. (Study of SilverHawk/TurboHawk in Lower Ex-
tremity Vessels [DEFINITIVE LE]; NCT00883246). (J Am Coll Cardiol Intv 2014;7:923–33) © 2014 by the American
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ABBR EV I A T I ON S
AND ACRONYMS
ABI = ankle-brachial index
CEC = clinical events
committee
CI = conﬁdence interval
CLI = critical limb ischemia
CTO = chronic total occlusion
DA = directional atherectomy
DCB = drug-coated balloon
DEP = distal embolic
protection
FDA = U.S. Food and Drug
Administration
PAD = peripheral arterial
disease
PSVR = peak systolic velocity
ratio
PTA = percutaneous
transluminal angioplasty
RC = Rutherford classiﬁcation
SFA = superﬁcial femoral
artery
and iDEV/A
is an equity
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924T he incidence of peripheral arterialdisease (PAD) is continuing to growworldwide, resulting in increasing
requirements for treatment and increasing
healthcare costs (1,2). In 2010, 202 million
people were living with PAD globally, an esti-
mated 23.5% increase over the previous
decade (1). In 2001, the estimated cost of
PAD in the United States was $4.37 billion
(3). Diabetes mellitus, the most prevalent
risk factor for PAD, currently affects 371SEE PAGE 934million people worldwide, and the incidence
is predicted to reach 552 million by 2030 (4,5).
PAD now affects 1 in 3 patients with diabetes
(6). Diabetic patients with PAD remain a chal-
lenge to treat. Previous studies have shown a
decrease in primary and secondary patency
following surgical bypass and endovascular
interventions in patients with diabetes
compared with those without diabetes (7–10).
Results of treatment with directional
atherectomy (DA), a modality designed to precisely
remove the obstructing arterial atheroma, have been
reported in multiple single-center and retrospective
studies (11–18). Patency rates at 12 months varied
widely from 54% to 84% depending on patient and
lesion characteristics, including recurrent stenosis,
method of follow-up, study deﬁnitions, and use of a
core laboratory for independent evaluation. Previous
PAD studies have shown a 10% to 15% decrease in the
patency rate when independently adjudicated by a
core laboratory compared with investigator-reported
patencies (19). DEFINITIVE LE (Determination of
EFfectiveness of the SilverHawk PerIpheral Plaque
ExcisioN System (SIlverHawk Device) for the Treat-
ment of Infrainguinal VEssels / Lower Extremities)
was a prospective study with core laboratory–
adjudicated data gathered in patients with claudica-
tion and CLI and with lesions up to 20 cm.
METHODS
DEFINITIVE LE was a prospective, multinational,
single-arm study designed to evaluate the acute and
12-month safety and effectiveness of DA for endo-
vascular treatment of 800 subjects with PAD. In the
DEFINITIVE LE study, there were no anatomicbbott. He is a noncompensated consultant for Boston Scientiﬁc, A
shareholder in Spirox, Primacea, TissueGen, CV Ingenuity, and
received March 17, 2014; revised manuscript received May 2, 20restrictions as to location of disease or the number of
inﬂow or outﬂow lesions in subjects with claudication
or critical limb ischemia (CLI). The study was con-
ducted in accordance with Good Clinical Practices and
applicable laws of all relevant governing bodies. Each
site’s institutional review board/ethics committee
reviewed and approved the study protocol. Before
enrollment, signed informed consent was required
for all subjects. A clinical events committee (CEC)
composed of independent physicians adjudicated
adverse events. Independent core laboratories con-
ducted analyses of and adjudicated angiographic
images (SynvaCor, Springﬁeld, Illinois) and duplex
ultrasound images (VasCore, Massachusetts General
Hospital, Boston, Massachusetts). Regular monitoring
visits were conducted at all investigational sites.
The primary endpoint for subjects with claudica-
tion (Rutherford classiﬁcation [RC] of 1 to 3) was
primary patency at 12 months deﬁned in the protocol
as duplex ultrasonography measurement of the peak
systolic velocity ratio (PSVR) #3.5 at the target le-
sion(s) with no clinically-driven reintervention
within the target segment. The primary endpoint of a
PSVR #3.5 was deﬁned at the creation of the study
and must be reported. The secondary endpoint for
primary patency was deﬁned as a PSVR #2.4, which
has since been clinically established as the more
appropriate value to detect restenosis. Therefore, a
PSVR #2.4 was used as the indicator of all other
patency rates reported in this paper. Clinically-driven
revascularization was deﬁned and monitored by the
CEC as reintervention due to $50% diameter stenosis
in the presence of recurrent symptoms or an
asymptomatic $70% stenosis in the treated segment.
A pre-speciﬁed hypothesis postulated that DA
treatment of claudicants with diabetes would have
noninferior primary patency at 12 months compared
with subjects without diabetes. Previous single-center
data evaluated the effectiveness of DA and revealed a
primary patency of 67% at 12 months in subjects with
claudication. In this study, diabetic subjects had a 12-
month primary patency of 60% and nondiabetic sub-
jects had a 12-month primary patency of 68% (14). In
the DEFINITIVE LE study, the sample size required to
evaluate the hypothesis of noninferior patency in
diabetic versus nondiabetic claudicants with 80% po-
wer was statistically derived with a 1-sided alpha of
0.05 and a noninferiority margin of 12%. The postu-
lated rate of primary patency at 1 year as per previousngioSculpt/Spectranetics, and Pathway/Volcano; and
Scion Cardiovascular.
14, accepted May 8, 2014.
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925workwas 60% in each subgroup, resulting in aminimal
sample size of 424 claudicant subjects. The overall
study was planned to evaluate both claudicants and
subjects with CLI with anticipated enrollment of 600
claudicants and 200 subjectswith CLI. This sample size
ensured that there would be adequate enrollment for
the diabetic versus nondiabetic subset analysis.
The primary endpoint for subjects with CLI (RC 4 to
6) was freedom from major unplanned amputation of
the target limb through 12 months. Major amputation
was deﬁned as amputation above themetatarsal region
that was unanticipated before the index procedure.
Pre-speciﬁed secondary endpoints included: 1)
device success, deﬁned as #30% residual angio-
graphic stenosis after DA without adjunctive in-
terventions; 2) procedural success, deﬁned as #30%
angiographic residual stenosis after DA and adjunc-
tive interventions; 3) primary patency rate at 12
months, PSVR #2.4; 4) secondary 12-month patency;
5) primary duplex core laboratory–conﬁrmed patency
in CLI subjects at 12 months; 6) major adverse event
rate at 30 days and 12 months, deﬁned as a composite
of clinically-driven target vessel revascularization,
major unplanned amputation of the treated limb, orTABLE 1 Inclusion and Exclusion Criteria
Inclusion criteria
Rutherford classiﬁcation 1–6.
Is willing and capable of complying with all follow-up evaluations
18 years of age of older
Provides written informed consent
Has evidence of $50% stenosis or occlusion in the superﬁcial femoral, po
by angiography
Has identiﬁable distal target vessel, which upon completion of the interv
Exchangeable guidewire must cross lesion(s) with catheter able to cross
Each discrete target lesion’s length is #20 cm
Reference vessel diameter is 1.5–7 mm
Exclusion criteria
Has $1 of the contraindications listed in the SilverHawk instructions for
Has a contraindication to antiplatelet therapy, anticoagulants, thromboly
Has a hypersensitivity to contrast material that cannot be adequately pre
Has known hypersensitivity to treatment device material
Has known uncontrollable hypercoagulable condition or refuses blood tr
Has life expectancy <12 months
Has surgical endovascular procedure of the target vessel within 14 days
Has planned surgical intervention or endovascular procedure within 30 d
Is currently participating in an investigational drug or device study
Has other comorbid condition(s) that precludes safe percutaneous interv
Has had a previous bypass affecting the target limb
Has end-stage renal disease
Has had a previous amputation above the metatarsal line on the target l
Has severe calciﬁcation in target lesion(s)
Has in-stent restenosis of the target lesion.
Has an aneurysmal target vessel
Has signiﬁcant stenosis or occlusion of inﬂow tract that has not been rev
Has perforation, dissection, or other injury of the access or target vesselall-cause mortality; 7) improvement in RC at
12 months; 8) improvement in ankle-brachial index
(ABI) at 12 months; 9) amputation-free survival in
subjects with claudication (baseline RC of 1 to 3) at 12
months; 10) wound healing at 3, 6, and 12 months in
subjects with a baseline RC of 5 to 6; and 11) quality-
of-life measurement Walking Impairment Question-
naire at 30 days and 12 months.
Patients with infrainguinal arterial lesions meeting
inclusion criteria were enrolled; selection criteria are
listed in Table 1. Signiﬁcant stenoses or occlusions of
inﬂow vessels (iliac or common femoral artery)
required successful revascularization before enroll-
ment. Multiple target lesions up to 20 cm regardless
of location (above the knee, involving the popliteal,
or below the knee) were allowed. A lesion was deﬁned
as single if the distance between stenoses was no
longer than 3 cm in the superﬁcial femoral artery
(SFA) and popliteal segments or 2 cm in the infrapo-
pliteal segments. If multiple diseased outﬂow vessels
were present, the treatment of any outﬂow vessel
nontarget lesion was left to the discretion of the
operator. However, if only a single outﬂow vessel was
present, then DA was required to treat that outﬂow.pliteal, anterior tibial, posterior tibial, and/or peroneal arteries, conﬁrmed
ention, is anticipated to provide reconstitution of blood ﬂow to the foot
lesion
use
tic drugs, or any other drug anticipated to be used
-treated
ansfusion
before the index procedure
ays after the index procedure
ention
imb
ascularized before treatment of the target vessel
requiring additional stenting or surgical intervention before enrollment
TABLE 2 Baseline Subject Characteristics
Claudicants
(n ¼ 598)
CLI
(n ¼ 201)
All
(N ¼ 799) p Value, CLD vs. CLI
Age, yrs 69.5  10.4 (598) 72.1  11.4 (201) 70.1  10.7 (799) 0.002
Female 43.8 (262/598) 50.2 (101/201) 45.4 (363/799) 0.120
Caucasian 71.7 (429/598) 64.7 (130/201) 70.0 (559/799) 0.062
History and risk factors
Diabetes mellitus 46.8 (280/598) 68.7 (138/201) 52.3 (418/799) <0.001
Angina pectoris 22.9 (137/598) 18.4 (37/201) 21.8 (174/799) 0.199
Cardiac arrhythmia 15.6 (93/598) 22.9 (46/201) 17.4 (139/799) 0.023
Congestive heart failure 13.2 (79/598) 17.9 (36/201) 14.4 (115/799) 0.104
Stroke 9.0 (54/598) 11.9 (24/201) 9.8 (78/799) 0.271
Myocardial infarction 18.6 (111/597) 18.9 (38/201) 18.7 (149/798) 0.916
CABG or PCI 39.5 (236/598) 32.3 (65/201) 37.7 (301/799) 0.077
Hypertension 92.0 (550/598) 92.0 (185/201) 92.0 (735/799) 1.000
Hyperlipidemia 86.1 (515/598) 76.1 (153/201) 83.6 (668/799) 0.001
Renal insufﬁciency 16.7 (100/598) 23.4 (47/201) 18.4 (147/799) 0.045
Nonhealing ischemic ulcers 2.0 (12/598) 56.2 (113/201) 15.6 (125/799) <0.001
Current or former smoker 53.5 (320/598) 35.8 (72/201) 49.1 (392/799) <0.001
Values are mean  SD (N) or % (n/N).
CABG ¼ coronary artery bypass graft; CLD ¼ claudicants; CLI ¼ critical limb ischemia; PCI ¼ percutaneous coronary intervention.
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926All subjects underwent revascularization of target
lesions of the femoropopliteal and/or tibial-peroneal
arteries using a DA device. If the DA device could
not initially pass through the lesion, pre-dilation was
performed to facilitate DA device passage. Angio-
graphic ﬁlms, including run off, were obtained
immediately before and after the atherectomy pro-
cedure to document pre- and post-treatment results.
Adjunctive procedures including percutaneous
transluminal angioplasty (PTA) were performed perTABLE 3 Baseline Lesion Characteristics
Lesion Characteristics
Claudicants
(n ¼ 743)
Target artery
SFA 72.1 (536/743)
Popliteal 15.3 (114/743)
Infrapopliteal 12.5 (93/743)
Lesion length, cm 7.5  5.3 (743)
Longest lesion per subject, cm 8.3  5.4 (598)
Pre-procedure reference vessel diameter, mm 4.3  1.1 (741)
Pre-procedure minimal lumen diameter, mm 1.2  0.9 (741)
Baseline stenosis 72.7  18.1 (741)
Occlusions 17.4 (129/741)
Calciﬁcation 37.1 (275/742)
De novo (site assessed) 93.5 (695/743)
Target lesion length, cm
$10.0 28.9 (215/743)
5.0–9.9 33.0 (245/743)
<5 38.1 (283/743)
Values are % (n/N) or mean  SD (N).
SFA ¼ superﬁcial femoral artery; other abbreviations as in Table 2.physician discretion; however, if residual stenosis
was <30%, additional post-dilation was not recom-
mended. Distal protection devices were used at the
discretion of the attending physician, as was the
type of periprocedural anticoagulation and anti-
platelet therapy.
Follow-up assessments and target lesion duplex
ultrasound examinations occurred at 30 days,
6 months, and 12 months. Each visit included assess-
ment of RC, Walking Impairment Questionnaire (forCLI
(n ¼ 279)
All
(N ¼ 1,022) p Value, CLD vs. CLI
48.4 (135/279) 65.7 (671/1,022) <0.001
17.2 (48/279) 15.9 (162/1,022) 0.501
34.4 (96/279) 18.5 (189/1,022) <0.001
7.2  5.5 (278) 7.4  5.3 (1,021) 0.381
8.3  5.7 (201) 8.3  5.5 (799) 0.926
3.7  1.3 (278) 4.2  1.2 (1,019) <0.001
0.9  0.9 (278) 1.1  0.9 (1,019) <0.001
75.9  20.0 (278) 73.6  18.7 (1,019) 0.015
29.9 (83/278) 20.8 (212/1,019) <0.001
37.1 (103/278) 37.1 (378/1,020) 1.000
87.1 (243/279) 91.8 (938/1,022) 0.001
24.8 (69/278) 27.8 (284/1,021) 0.209
32.0 (89/278) 32.7 (334/1,021) 0.822
43.2 (120/278) 39.5 (403/1,021) 0.150
TABLE 4 Procedural Characteristics
Claudicants CLI Total p Value, CLD vs. CLI
Procedure time, min 60.0 (43.0–89.0) [596] 77.0 (51.0–100.0) [201] 65.0 (45.0–92.0) [797] <0.001
Contrast administered, ml 140.0 (90.0–210.0) [593] 135.0 (95.0–200.0) [200] 140.0 (90.0–207.0) [793] 0.772
Fluoroscopy time, min: 16.0 (10.0–24.0) [592] 19.0 (13.0–29.0) [194] 16.0 (11.0–25.0) [786] <0.001
Embolic protection 20.6 (598) 27.9 (201) 22.4 (799) 0.039
SpiderFX only 20.2 (598) 27.4 (201) 22.0 (799) 0.038
Device success (core laboratory)* 75.9 (727) 72.1 (269) 74.9 (996) 0.218
Post-device stenosis, %* 23.9  13.1 (727) 25.6  13.8 (269) 24.3  13.3 (996) 0.073
Procedure success (core laboratory)* 91.3 (738) 83.0 (277) 89.1 (1,015) <0.001
Post-adjunctive stenosis, %* 18.0  11.0 (278) 20.9  12.3 (81) 18.6  11.4 (359) 0.045
Values are median (interquartile range) [n], % (n), or mean  SD (n). *Lesion level characteristics.
Abbreviations as in Table 2.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 8 , 2 0 1 4 McKinsey et al.
A U G U S T 2 0 1 4 : 9 2 3 – 3 3 DEFINITIVE LE Trial: Final Results
927subjects without tissue loss [baseline RC 1 to 4]), EQ-5D
questionnaire, ABI, and adverse event evaluations. In
addition, subjects with a RC of 5 and 6 at baseline had
wound assessments at each follow-up visit, including
an additional visit at 3months.Woundswere classiﬁed
using the Wagner Classiﬁcation System. All target le-
sions were analyzed as identiﬁed by the angiographic
core laboratory.TABLE 5 Periprocedural Events, Days 0 to 30
Event Type
Claudicants
(n ¼ 598)
Any periprocedural event 10.7 (64)
Requiring treatment 7.7 (46)
Distal embolization 2.5 (15)
Requiring treatment 1.2 (7)
Surgical intervention 0 (0)
Stenting 0.2 (1)
PTA/lysis/embolectomy/aspiration 1.0 (6)
Abrupt closure 0.7 (4)
Requiring treatment 0.5 (3)
Surgical intervention 0.5 (3)
Stenting 0 (0)
PTA 0 (0)
Dissection (ﬂow limiting) 2.2 (13)
Requiring treatment 1.3 (8)
Surgical intervention 0 (0)
Stenting 0.7 (4)
PTA 0.7 (4)
Perforation 6.2 (37)
Requiring treatment 5.0 (30)
Surgical intervention 0.2 (1)
Stenting 2.3 (14)
PTA 2.5 (15)
Aneurysm 0.5 (3)
Requiring treatment 0.3 (2)
Surgical intervention 0 (0)
Stenting 0.3 (2)
PTA 0 (0)
Values are % (n).
PTA ¼ percutaneous transluminal angioplasty; other abbreviations as in Table 2.All statistical analyses were performed using SAS
for Windows version 9.1 or higher (SAS Institute Inc.,
Cary, North Carolina). Continuous variables pre-
sented as mean  SD were evaluated with t tests,
whereas continuous variables presented as median
(interquartile range) were evaluated with the Wil-
coxon rank sum test for independent samples or
Wilcoxon signed rank test for pairwise comparisons.CLI
(n ¼ 201)
All
(N ¼ 799) p Value, CLD vs. CLI
12.9 (26) 11.3 (90) 0.3703
7.5 (15) 7.6 (61)
7.5 (15) 3.8 (30) 0.004
3.0 (6) 1.6 (13)
0.5 (1) 0.1 (1)
0 (0) 0.1 (1)
2.5 (5) 1.4 (11)
6.0 (12) 2.0 (16) <0.001
4.5 (9) 1.5 (12)
2.5 (5) 1.0 (8)
0.5 (1) 0.1 (1)
1.5 (3) 0.4 (3)
2.5 (5) 2.3 (18) 0.786
2.0 (4) 1.5 (12)
0 (0) 0 (0)
2.0 (4) 1.0 (8)
0 (0) 0.5 (4)
2.5 (5) 5.3 (42) 0.044
1.5 (3) 4.1 (33)
0 (0) 0.1 (1)
0.5 (1) 1.9 (15)
1.0 (2) 2.1 (17)
0 (0) 0.4 (3) 0.576
0 (0) 0.3 (2)
0 (0) 0 (0)
0 (0) 0.3 (2)
0 (0) 0 (0)
FIGURE 1 Patency Outcomes: Claudicant Cohort
Kaplan-Meier estimates of patency by lesion. The red line represents the
primary patency rate deﬁned as a peak systolic velocity ratio (PSVR) #3.5,
and the blue line represents primary patency deﬁned as a PSVR #2.4.
CI ¼ conﬁdence interval.
FIGURE
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928For continuous variables collected at multiple time
points, change scores from baseline were computed
and used for the basis of analysis. Binary categorical
variables are evaluated with the Fisher exact test and2 Patency Outcomes: Diabetic Versus Nondiabetic Claudicants
Meier estimates of patency (peak systolic velocity ratio #2.4) by
I ¼ conﬁdence interval.ordinal variables with Mantel-Haenszel chi-square.
p values are 2 sided, with values <0.05 deemed sta-
tistically signiﬁcant. No adjustments for multiple
comparisons were performed. The primary endpoints
are analyzed and presented using Kaplan-Meier time-
to-event methods; estimates of incidence were taken
at 12 months post-intervention. The study was pro-
spectively powered to test the hypothesis that clau-
dicants with diabetes would have noninferior primary
patency at 12 months compared with nondiabetic
claudicants when treated with DA. Noninferiority was
tested using Blackwelder’s method.
RESULTS
From April 2009 to April 2011, 800 subjects at
47 multinational centers were treated with DA using
the SilverHawk and/or TurboHawk Atherectomy De-
vices (Covidien, Plymouth, Minnesota). Mean age was
70.1  10.7 years; 55% were male, and 52.3% had
diabetes (Table 2). One subject’s data were excluded
from all analyses due to an invalid informed consent,
yielding a cohort of 799 analyzable subjects.
A total of 1,022 target lesions were treated, the
mean longest lesion per patient was 8.3  5.5 cm, 28%
had a lesion length >10 cm, and 21% were total oc-
clusions (Table 3). Although the most proximal aspect
of target lesions was used to identify lesion location,
the lesion could extend up to 20 cm into more distal
arterial segments. Because multiple target lesions
were allowed per treated limb, each target lesion was
classiﬁed separately.
The median procedure time (arterial access to
catheter removal) was 65.0 min (45.0 to 92.0 min)
(Table 4). Predictors of a longer procedure time
included CLI, longer target lesions, greater baseline
severity of stenosis, number of lesions, distal embolic
protection utilization, and arterial calciﬁcation. Pre-
dilation was performed with small PTA balloons to
allow passage of the DA device, so as not to have a
therapeutic angioplasty effect on the target lesion.
Pre-dilation to allow DA passage was performed in
8.3% of lesions in claudicants and in 15.8% of lesions
in CLI subjects; 75% of PTA balloons were #3 mm in
diameter, and the mean inﬂation pressure was 6.5
atm. By multivariate analysis, predictors of need for
pre-dilation of the target lesion included calciﬁcation,
chronic total occlusion (CTO), small MLD, de novo,
higher Rutherford Category, age, and diabetes (p #
0.05). Adjunctive therapy after DA treatment was
performed in 35.3% (claudicants, 38.0%; CLI, 30.2%).
At investigator discretion, 20% of lesions that
had <30% residual stenosis after DA (per core labo-
ratory assessment) still underwent adjunctive PTA.
TABLE 6 Primary Patency Rate (PSVR #2.4) in Claudicant Cohort
by Lesion Length and Location
Primary Patency (PSVR #2.4) in Claudicant Cohort
Subgroup n
Mean Lesion
Length, cm
12-Month
Patency Rate, %
All 743 7.5 78
SFA 536 8.1 75
<5 cm 183 2.7 79
5–9.9 cm 168 7.0 83
$10 cm 185 14.6 65
Popliteal 114 6.0 77
<5 cm 48 2.5 84
5–9.9 cm 48 6.8 74
$10 cm 18 13.1 65
Infrapopliteal 93 5.5 90
<5 cm 52 2.7 90
5–9.9 cm 29 7.2 88
$10 cm 12 13.4 91
Primary Patency (PSVR #2.4) in CLI Cohort
Subgroup n
Mean Lesion
Length, cm
12-Month
Patency Rate, %
All 279 7.2 71
SFA 135 8.6 68
<5 cm 45 2.6 75
5–9.9 cm 41 7.2 65
$10 cm 48 15.5 63
Popliteal 48 5.4 67
<5 cm 27 3.0 78
5–9.9 cm 16 7.1 50
$10 cm 5 13.5 75
Infrapopliteal 96 6.0 78
<5 cm 48 2.5 79
5–9.9 cm 32 6.9 79
$10 cm 16 14.4 73
PSVR ¼ peak systolic velocity ratio; other abbreviations as in Table 2.
FIGURE 3 Endpoint Outcomes: CLI Cohort
Kaplan-Meier estimates of outcomes in the critical limb ischemia (CLI) cohort.
CI ¼ conﬁdence interval.
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929The adjunctive stent rate was 3.2%, including a 1.9%
stent rate to treat a perforation.
Device success (deﬁned as #30% residual stenosis
in target lesions after DA) was reported as 87%
by the investigators. Independent angiographic core
laboratory assessment reported a 74.9% (95% conﬁ-
dence interval [CI]: 72.0% to 77.6%) device success.
Procedural success (DA plus post-DA adjunctive pro-
cedures) was investigator reported in 99% of lesions
(claudicants, 100%; CLI, 98%). The angiographic core
laboratory assessment revealed 89.1% (95% CI: 86.9%
to 90.9%) procedural success (claudicants, 91.3%
[95% CI: 89.0% to 93.3%]; CLI, 83.0% [95% CI: 78.0%
to 87.3%]). On univariate analysis, predictors of
greater procedural success included female gender,
SFA lesions, smaller diameter stenosis, absence of
calciﬁcation, and shorter lesion length.
The most common periprocedural adverse event
was arterial perforation at 5.3% (Table 5). Perforationsfrom any source were included, whether from DA, wire
passage, or adjunctive therapy. Distal embolization
was noted in 30 of 799 (3.8%) subjects as reported by
the investigator or angiographic core laboratory, or
adjudicated by the CEC. In total, 13 subjects (1.6%)
were noted to have distal embolizations and under-
went additional intervention during the primary pro-
cedure (endovascular therapy in 12 and surgical
intervention in 1).
Occluded lesions were present in 127 claudicants
and 81 CLI subjects. The rate of periprocedural com-
plications requiring treatment was higher in subjects
with occluded lesions: 11.5% (24 of 208) versus 6.3%
(37 of 591) (p ¼ 0.022) through 30 days. The most
frequent complication was perforation requiring
treatment with a rate of 4.8% (10 of 208) in the oc-
clusion subgroup versus 3.9% (23 of 591) (p ¼ 0.548)
in the nonoccluded group. The frequency of abrupt
closures requiring treatment was 3.8% (8 of 208) in
the CTO subgroup compared with 0.7% (4 of 591) (p ¼
0.003) in the non-CTO subgroup.
A total of 22.4% of subjects had procedures per-
formed with distal embolic protection (DEP) via a ﬁlter
device (98.3% of those with the SpiderFX Embolic
Protection System [Covidien]. DEP was used more
frequently in CLI subjects than in claudicants (27.9%
vs. 20.6%). The material captured in the DEP device
was not pathologically analyzed. Embolization
TABLE 7 Functional Outcomes Through 12 Months
Baseline
30-Day
Follow-Up
12-Month
Follow-Up
RC clinical category
All 3.0 (2.0–4.0) 1.0 (0.0–2.0) 1.0 (0.0–2.0)
Claudicant 3.0 (2.0–3.0) 1.0 (0.0–2.0) 1.0 (0.0–2.0)
CLI 5.0 (4.0–5.0) 4.0 (1.0–5.0) 1.0 (0.0–3.0)
Ankle-brachial index
All 0.65  0.16 0.90  0.18 0.83  0.21
Claudicant 0.67  0.15 0.91  0.17 0.84  0.20
CLI 0.59  0.18 0.87  0.23 0.77  0.26
Walking Impairment
Questionnaire
(baseline RC 1–3
only)
Pain 50.0 (37.5–75.0) 75.0 (62.5–100.0) 87.5 (62.5–100.0)
Walking distance 9.3 (2.3–27.6) 34.7 (7.3–89.3) 44.6 (12.6–89.3)
Walking speed 14.1 (3.3–30.4) 30.4 (10.9–50.0) 35.9 (17.4–56.5)
Stair climbing 20.8 (4.2–54.2) 45.8 (8.3–87.5) 54.2 (16.7–87.5)
EQ-5D Index
All 0.78 (0.68–0.81) 0.81 (0.76–1.00) 0.82 (0.77–1.00)
Claudicant 0.78 (0.71–0.82) 0.83 (0.78–1.00) 0.83 (0.78–1.00)
CLI 0.75 (0.45–0.78) 0.78 (0.68–0.84) 0.78 (0.71–0.84)
EQ-5D Visual Analog
Scale
All 65.0  19.2 71.0  20.1 71.8  18.8
Claudicant 66.6  18.3 72.8  19.2 72.3  19.0
CLI 60.2  20.8 65.3  21.7 70.2  18.0
Wound healing (baseline
RC 5–6 only)
Wagnar score 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.0 (0.0–1.0)
Data presented as median (interquartile range) or mean  SD. All changes from baseline to 30
days and 12 months are statistically signiﬁcant (p < 0.05).
CLI ¼ critical limb ischemia; RC ¼ Rutherford classiﬁcation.
McKinsey et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 8 , 2 0 1 4
DEFINITIVE LE Trial: Final Results A U G U S T 2 0 1 4 : 9 2 3 – 3 3
930occurring at any time during the procedure, including
crossing the lesion pre-atherectomy, were included in
the analysis. Positive evidence of distal embolization
associated with DEP was deﬁned as an embolus distal
to the DEP device or remaining after the removal of the
DEP device. No signiﬁcant difference in the rate of
distal embolization was noted (3.6% [22 of 620]
without DEP vs. 4.5% [8 of 179] with DEP, p ¼ 0.512).
However, direct comparison is confounded by the useTABLE 8 SFA Patency Comparison
Study Device Mean L
DEFINITIVE LE* DA 8
RESILIENT (20) Bare-metal stent 6
DURABILITY II (22) Bare-metal stent 8
STRIDES (33) Drug-eluting stent 9
Zilver RCT (21) Drug-eluting stent 5
Italian Registry (25) Drug-coated balloon 7
LEVANT I (34) Drug-coated balloon 8
*Data from superﬁcial femoral artery (SFA) lesions in claudicant cohort.
DA ¼ directional atherectomy; PSVR ¼ peak systolic velocity ratio; RCT ¼ randomizedof DEPwith longer,more stenotic, and heavily calciﬁed
lesions. Of the 8 subjects with embolic events despite
DEP use, 3 were associated with treatment of isolated
SFA lesions, 1 with an isolated infrapopliteal lesion,
and 4 with multivessel treatment. Of these 8 emboli-
zations, 3 subjects required no further treatment and 5
subjects underwent aspiration or PTA with clearing of
the embolus.
The 30-day major adverse event rate was 1.6%
(95% CI: 0.8% to 2.8%) including 4 deaths (0.5%)
(3 myocardial infarctions, 1 cardiogenic shock) and
6 clinically-driven target lesion revascularizations
(0.9%). There were 3 major unplanned amputations
(0.4%; 1 above knee, 1 below knee, 1 Syme’s), all in
CLI subjects. Major adverse events were more com-
mon among CLI subjects (3.5% vs. 1.0% in claudi-
cants, p ¼ 0.024). None of the deaths within 30 days
were adjudicated by the CEC as related to either the
study device or the index procedure.
Primary patency reported across all anatomic
vascular beds in the claudicant cohort (598 subjects
with 743 lesions) at 12 months was 81.5% (PSVR #3.5
and no reintervention for target lesions). Primary
patency at 12 months, using the now more accepted
endpoint of PSVR #2.4, was 78% (95% CI: 74.0% to
80.6%) (Fig. 1). The pre-speciﬁed noninferiority hy-
pothesis of DA patency in diabetic versus nondia-
betic subjects with claudication was met (77% [95%
CI: 71.7% to 81.4%] diabetic vs. 78% [95% CI: 72.9%
to 82.1%] nondiabetic) (noninferiority, p < 0.001;
superiority, p ¼ 0.98, using a PSVR #2.4) (Fig. 2). In
moderate-length lesions (5.0 to 9.9 cm), patency
rates were 83% in the SFA, 74% in the pop-
litealartery, and 88% in the infrapopliteal artery. The
patency rates in longer lesions ($10 cm) were 65% in
the SFA and popliteal arteries. Patency was 88% to
91% for infrapopliteal lesions irrespective of length
(Table 6). Secondary 12-month patency among clau-
dicants was 89% overall.
The primary endpoint of CLI subjects at 12 months
(freedom from target limb major amputation) wasength, cm Patency, % Patency Deﬁnition, PSVR
.1 75 #2.4
.2 81.3 <2.5
.9 77.2 <2.0
.0 68 <2.5
.4 83.1 <2.0
.6 83.7 <2.5
.1 67 <2.5
controlled trial.
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93195% (95% CI: 90.7% to 97.4%). Duplex-determined
primary patency in all CLI lesions, a pre-speciﬁed
secondary endpoint, was 71% (95% CI: 64.6% to
76.5%) and secondary patency was 88% (95% CI:
82.9% to 92.1%) (Fig. 3, Table 6). Target lesion location
patency at 12 months in CLI subjects was as follows:
SFA, 68%; popliteal artery, 67%; and infrapopliteal
artery, 78%. The patency rate in the CTO lesions was
63.3% in the claudicants (mean lesion length, 11.2 cm)
and 65.5% in the CLI cohort, with a mean length of
10.3 cm. Lesion patency at 12 months in pre-dilation
versus non–pre-dilation was 87.5% versus 76.6%
(p ¼ 0.2) in claudication subjects and 56.4% versus
73.7% (p ¼ 0.021) in CLI subjects, respectively.
Functional clinical outcomes for ABI, RC, and
quality-of-life measurements for both claudicant
and CLI subjects revealed statistically signiﬁcant
(p < 0.05) improvement in all categories at 30 days
and 12 months (Table 7).
DISCUSSION
The DEFINITIVE LE study objectively evaluated, with
independent core laboratory and CEC adjudication,
the acute safety and 12-month durability of DA in the
treatment of infrainguinal PAD in claudicants and
CLI subjects. This study demonstrated effective
debulking to #30% diameter stenosis in lesions up to
20 cm in length using DA with selective adjunctive
PTA. Stent placement rate was a very low 3.2%,
dramatically lower than the 40% to 50% bail-out
rates reported in the PTA arms of recent stent
studies (20,21). Critically, the patency rates observed
in DEFINITIVE LE are similar to the rates published
in SFA studies of second-generation nitinol stents
(Table 8). Although direct comparisons cannot be
made given the heterogeneity of the subjects studied
across all protocols, the DEFINITIVE LE study dem-
onstrates that DA has results comparable to those
of other contemporary technologies treating infrain-
guinal PAD but with the distinct advantage of
rarely leaving a permanent implant in place. The
DEFINITIVE LE study was not limited to a speciﬁc
lesion or subset of lesions, and, as such, it is able to
provide scientiﬁc information across many anatomic
locations and subject subsets.
Lesion length is a predictor of long-term patency
for most endovascular therapies (20–22). In the
DEFINITIVE LE study, the mean lesion length was 7.5
cm, the longest mean lesion was 8.3 cm, and 28% of
lesions were >10 cm in length. The RESILIENT (Ran-
domized Study Comparing the Edwards Self-
ExpandIng Lifestent versus Angioplasty Alone In
LEsions INvolving The SFA and/or Proximal PoplitealArtery) randomized study allowed treatment of mul-
tiple lesions. The mean per-subject lesion length was
7.1 cm (20), but the individual mean lesion length was
6.2 cm, as noted in device labelling. The observed
patency rate was 81.3%. DURABILITY II (StuDy for
EvalUating EndovasculaR TreAtments of Lesions in
the Superﬁcial Femoral Artery and Proximal Popliteal
By usIng the Protege EverfLex NitInol STent SYstem
II) (22) reported a 77.2% primary patency rate (8.9-cm
mean lesion length) and the Zilver PTX drug-eluting
stent (Cook Medical, Bloomington, Indiana) ach-
ieved a primary patency rate of 83.1% in lesions with
a mean length of 5.4 cm (21). The DEFINITIVE LE data,
although not randomized, compare favorably with
outcomes of these trials (Table 8). Further, across
multiple anatomic segments, DA provided a similar
primary patency with selective adjunctive PTA.
Treatment of infrapopliteal lesions includes athe-
rectomy, PTA alone, or PTA with stenting, generally
with a coronary drug-eluting stent in very short le-
sions. The ACHILLES study evaluated the effective-
ness of infrapopliteal treatment of PAD (RC 3 to 5)
with DES versus PTA alone in 200 subjects (23). The
mean lesion length was 2.69  2.09 cm, and the 1-year
patency rate was 75% for drug-eluting stents and
57.1% for PTA alone. The limb salvage rate at 1 year
was 86% and 80%, in the DES and PTA groups
respectively. This core laboratory–controlled trial
revealed lower patency and limb salvage rates with
use of PTA and drug-eluting stents compared with the
DA infrapopliteal data reported in this study.
DEFINITIVE LE claudicants with infrapopliteal le-
sions had a 5.5-cm mean lesion length and a 90%
primary patency rate; CLI subjects had a 6.0-cm mean
lesion length, a 78% primary patency rate, and a 95%
limb salvage rate. Interestingly, the longer lesions in
the infrapopliteal arteries, regardless of diabetic sta-
tus, showed better patency outcomes than similar
length lesions in the SFA and popliteal arteries.
Drug-coated balloons (DCBs) are proving to be an
effective treatment option that does not require a
permanent endoprosthesis. However, rates of bail-
out stenting in the treatment arms of DCB studies
range from 4% in the THUNDER (Local Taxane with
Short Exposure for Reduction of Restenosis in Distal
Arteries) study (24), to 12.3% in the Italian Registry
(25), and 21% in the PACIFIER study (26). Combining
upfront atherectomy with DCB angioplasty may
overcome the current limitations of DCB angioplasty
such as lesion calciﬁcation, as reported by Cioppa
et al. (12). This group treated 30 subjects with severe
calciﬁcation with DA followed by a DCB. Bail-out
stents were necessary in only 2 subjects (6.5%), and
the primary patency rate at 1 year was 90%.
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932A unique attribute of the DEFINITIVE LE study
design was the pre-speciﬁed noninferiority hypothe-
sis for 12-month patency of diabetic to nondiabetic
subjects, which was met (77% vs. 78%; noninferiority,
p < 0.001; superiority, p ¼ 0.98). With increased
scrutiny regarding healthcare cost, effectiveness and
durability of treatment modalities are required. Most
studies do not stratify outcomes by diabetic status,
but previous work has demonstrated worse outcomes
with open and endovascular therapy in diabetic
patients compared with nondiabetic patients (7,8). An
exception to this statement is the retrospective,
nonpowered, ad-hoc analysis of the Zilver PTX reg-
istry, which found similar rates of patency as reported
by sites regardless of diabetes status (27).
The limb salvage rate of 95% observed in the
DEFINITIVE LE CLI cohort is higher than the CLI
surgical bypass studies that reported rates between
81% and 87% (28–30) and the PTA arm of the BASIL
(Bypass versus Angioplasty in Severe Ischaemia of the
Leg) study that reported a rate of 71% (31). Complete
wound healing in DEFINITIVE LE subjects with an RC
5 or 6 at baseline was 72% at 12 months. This is
comparable to the rates seen in bypass studies of CLI
subjects (74% to 75%) (28–30).
The DEFINITIVE LE study has conﬁrmed the safety
in treatment of subjects with single-level to multi-
level lower extremity disease and conﬁrmed the
durability of DA across a broad spectrum of subjects.
Indeed, the ability to treat multilevel disease with a
single device and to have an adjunctive stent rate just
over 3% and a patency rate consistent with rates of
previous primary stent trials indicates that DA is a
very effective therapy for patients with PAD who
present with either claudication or CLI.
STUDY LIMITATIONS. The study’s principal limita-
tions include a lack of randomization and follow-up
beyond 12 months. At the time of the creation of the
DEFINITIVE LE study protocol, there were no self-
expanding stents with U.S. Food and Drug Adminis-
tration (FDA) approval for PAD treatment. Therefore,
randomization to a control group would have beenlimited to PTA alone, which would have had an ex-
pected primary 12-month patency rate of 33%, per the
VIVA Performance Goal (32). However, the large
group of subjects enrolled and the adjudication
through core laboratory analyses overcame many of
these limitations. Another limitation is the use of a
PSVR >3.5 as the primary endpoint for restenosis in
the claudication group. After the ﬁnalization of the
study protocol, it became more accepted to use a
PSVR >2.4 as an indicator of restenosis. Fortunately,
that endpoint was used as a secondary endpoint, and
all data points and patencies have been expressed in
this paper using the secondary endpoint deﬁnition
rather than the primary endpoint deﬁnition. Addi-
tionally, these data should not be extrapolated to
other FDA-approved atherectomy devices because
their mechanisms of action differ from those of DA.
Studies with randomization of all FDA-approved
treatment modalities such as the recent National In-
stitutes of Health–funded BEST (Best Endovascular
vs. Best Surgical Therapy in Patients With Critical
Limb Ischemia) trial will be required to further clarify
the role of each of the treatment modalities.
CONCLUSIONS
The DEFINITIVE LE study conﬁrmed that DA is a safe
and effective treatment modality through 12 months
for patients with claudication and CLI. Furthermore,
DA was shown to be noninferior for treating PAD in
patients with diabetes compared with nondiabetic
patients.
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APPENDIX For a listing of the investigators
involved in the DEFINITIVE LE Study, please see
the online version of this article.
